Rite Aid (RAD) Reports In-Line Q3 EPS; Eases FY14 EPS Outlook
Tweet
Share
E-mailGet Alerts RAD Hot Sheet
Price: $0.65 --0%
Financial Fact:
Selling, general and administrative expenses: 1.78B
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Selling, general and administrative expenses: 1.78B
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Rite Aid (NYSE: RAD) reported Q3 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $6.36 billion versus the consensus estimate of $6.3 billion.
Same store sales for the quarter increased 2.3 percent over the prior year’s 13-week period, consisting of a 3.5 percent increase in pharmacy sales, partially offset by a 0.2 percent decrease in front end sales. Pharmacy sales included an approximate 88 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores increased 0.7 percent over the prior year period. Prescription sales accounted for 68.6 percent of total drugstore sales, and third party prescription revenue was 97.1 percent of pharmacy sales.
Sees FY2014 EPS of $0.17 - $0.23, versus the consensus of $0.24. Also sees FY2014 revenue of $25.3 - $25.425 billion, versus the consensus of $25.36 billion.
For earnings history and earnings-related data on Rite Aid (RAD) click here.
Same store sales for the quarter increased 2.3 percent over the prior year’s 13-week period, consisting of a 3.5 percent increase in pharmacy sales, partially offset by a 0.2 percent decrease in front end sales. Pharmacy sales included an approximate 88 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores increased 0.7 percent over the prior year period. Prescription sales accounted for 68.6 percent of total drugstore sales, and third party prescription revenue was 97.1 percent of pharmacy sales.
Sees FY2014 EPS of $0.17 - $0.23, versus the consensus of $0.24. Also sees FY2014 revenue of $25.3 - $25.425 billion, versus the consensus of $25.36 billion.
For earnings history and earnings-related data on Rite Aid (RAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Marpai, Inc. (MRAI) Misses Q2 EPS by 18c
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Corp. News, Hot Guidance, Retail SalesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
